As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?

The recent FDA approval in multiple myeloma of isatuximab (Sarclisa; Sanofi) marked a significant advance for patients newly diagnosed with the disease. When added to the triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd), the combination reduced the risk of disease progression and death by 40% compared with the VRd triplet alone for patients who cannot receive a transplant.¹